A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung

BACKGROUND: Recent advances have shown that histology and genetic biomarkers are important in patient selection, which have led to significantly better outcomes for lung cancer patients. However, most new treatments only apply to adenocarcinoma or non-squamous, and in squamous carcinoma there is lit...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jin-Ji, Huang, Cheng, Chen, Gong-Yan, Song, Yong, Cheng, Ying, Yan, Hong-Hong, Zhou, Qing, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4179224/
https://www.ncbi.nlm.nih.gov/pubmed/25239521
http://dx.doi.org/10.1186/1471-2407-14-684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4179224/
https://www.ncbi.nlm.nih.gov/pubmed/25239521
http://dx.doi.org/10.1186/1471-2407-14-684

Ejemplares similares